Insurance coverage for experimental technologies.
As the number and cost of new technologies grow, it is increasingly important that we develop sound policies for payment for those technologies while their clinical impacts are being defined. Such policies need to balance social interests in promotion of innovation, early access to promising technology, patient safety, control of health care costs, and return on investment. We present a rationale, policy options, and a proposal for insurance coverage of experimental technology.
Steinberg
E P
EP
Johns Hopkins School of Medicine, USA.
Tunis
S
S
Shapiro
D
D
D003659:Decision Making, Organizational; D018795:Device Approval; D004059:Diffusion of Innovation; D035082:Federal Government; D015276:Health Care Rationing; D007342:Insurance Benefits; D012109:Research Support as Topic; D018570:Risk Assessment; D013673:Technology Assessment, Biomedical / Q000191:economics*; D036302:Therapeutic Human Experimentation; D035703:Therapies, Investigational; D014481:United States